Skip to content
中文EN

Oncology

Tumor biology and anticancer therapy: from mechanism papers to pivotal readouts and launches.

669 picksRelatedImmunotherapyTumor microenvironmentADCs & conjugates

Latest picks

41–58 of 669
Oct 16Fri
  1. bioRxiv62

    Targeting proteasome composition reprograms tumor-intrinsic inflammation through selective degradation of STAT1

    A covalent small molecule that binds a dynamic pocket in the non-catalytic proteasome regulator PSME4 reprograms tumor-intrinsic inflammation. Blocking or reducing PSME4 with the probe and orthogonal genetic perturbations stabilized STAT1, restored interferon-associated transcription, enhanced antigen presentation, and disrupted IL-6/STAT3 signaling, suppressing tumor growth in vivo. The work defines a PSME4-STAT1-STAT3 axis and a framework for drugging non-catalytic proteasome regulators to alter tumor immunity.

    Why it matters: It provides a chemical probe and mechanism for targeting a non-catalytic proteasome regulator to reprogram tumor immunity.

  2. EMA61

    Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 October 2026

    The EMA's CHMP recommended six new medicines at its October 2026 meeting, including Rasonque (daraxonrasib) for previously treated metastatic pancreatic adenocarcinoma and Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist for weight management and type 2 diabetes in adults. It also backed Yuviwel (navepegritide) for achondroplasia in children, biosimilars of ranibizumab and filgrastim, and Kizfizo (temozolomide) for glioblastoma and malignant glioma. The committee confirmed refusal of Yartemlea (narsoplimab) after re-examination, and companies withdrew indication-extension applications for Ibrance and Truqap.

    Why it matters: First EU approval recommendations for daraxonrasib and oral orforglipron plus key withdrawal and refusal decisions affecting patient access.

  3. Nature48

    EGFR-targeted antibody−toxin conjugate in recurrent glioma: a phase 1 trial

    A phase 1 trial of D2C7-ATC, an antibody-toxin conjugate targeting EGFR and EGFRvIII, in patients with recurrent malignant glioma showed encouraging safety and efficacy signals. Translational analyses of patient samples indicated intratumoral and systemic immune activation. The results support the conjugate as a candidate strategy for recurrent malignant glioma.

    Why it matters: Phase 1 data on an EGFR/EGFRvIII-targeted antibody-toxin conjugate in recurrent malignant glioma with immune activation evidence.

  4. Medical Xpress64

    Lactation drug could reduce breast cancer risk after childbirth, study suggests

    An international team led by UBC reports in Cancer Discovery that analyzing health records of more than 150,000 women in Spain and Norway found those who used cabergoline to suppress lactation had about 70% lower breast cancer incidence in subsequent years. In mice carrying BRCA1 and TP53 mutations, a single dose cut tumor incidence by about half; the researchers plan a multinational clinical trial in BRCA1 carriers to confirm the findings. DOI: 10.1158/2159-8290.CD-26-0187.

    Why it matters: The brief gives both the Spain-Norway cohort and BRCA1/TP53 mouse evidence, and cabergoline is already approved.

  5. Medical Xpress67

    Lab-grown tumors reveal immune cells capable of killing small cell lung cancer

    A WEHI team published a study in Cancer Cell using patient-derived mini tumor models showing that gamma delta T cells can recognize and kill small cell lung cancer (SCLC). Patients whose tumors contained more of these cells had longer survival.

    Why it matters: The study links gamma delta T cell killing of SCLC with repurposing approved drugs, offering a concrete translational path.

  6. WeChat66

    Broad-Spectrum RAS Inhibitor Daraxonrasib Wins FDA Approval in Metastatic Pancreatic Cancer

    The broad-spectrum RAS inhibitor daraxonrasib received FDA approval on August 26 for metastatic pancreatic cancer in adults who have received at least one prior systemic therapy or are not suitable for multi-drug combination systemic therapy. Unlike KRAS G12C inhibitors, it covers mutations including G12V, G12D, G13 and Q61, and the article also notes strong efficacy in lung cancer.

    Why it matters: First approval extending RAS inhibition beyond KRAS G12C to multiple RAS mutations in pancreatic cancer.

  7. 顶刊论文（社媒热度）53

    Personalized neoantigen-targeting cancer vaccines in ovarian cancer: a phase 1 trial.

    A personalized neoantigen long-peptide vaccine (NeoVax with poly-ICLC), combined with delayed anti-PD-1 antibody, was feasible and safe in ten patients with platinum-sensitive high-grade epithelial ovarian cancer after platinum doublet chemotherapy. Nine of twelve evaluable Cohort B patients were vaccinated (75%, 90% CI 47-93%), over 70% of targets remained detectable in cell-free DNA despite a median 6.5-month biopsy-to-vaccine interval, and biomarker analysis suggested biologic activity in six of ten patients. Resistant tumor clones showed defects in antigen presentation, consistent with vaccine-driven immune pressure.

    Why it matters: Shows personalized neoantigen vaccination is feasible and immunologically active in ovarian cancer, a tumor type with few such data.

  8. WeChat70

    Tumor Cells Use SLC52A2 to Seize Vitamin B2 and Drive T Cell Ferroptosis

    Tumor cells outcompete T cells for vitamin B2 (riboflavin) in the tumor microenvironment by preferentially using the transporter SLC52A2 rather than the SLC52A3 that T cells rely on. Riboflavin is converted to FMN and FAD, cofactors central to mitochondrial energy production and antioxidant defense, and its depletion promotes ferroptosis, a 2012-named iron-dependent form of cell death marked by lipid peroxide accumulation, in T lymphocytes. The finding points to nutrient competition as a mechanism of immune suppression in solid tumors.

    Why it matters: It identifies SLC52A2-mediated riboflavin competition as a new route to T cell ferroptosis in solid tumors.

  9. YouTube76

    Ultrasound mechanogenetics drives tunable CAR-T and in situ intratumoral antigen induction for cancer immunotherapy

    Shao Wang's team at the University of Southern California presented an ultrasound mechanogenetics platform in an ImmuneZoom YouTube lecture. Heat shock promoters or Piezo1 channels induce CD19 in situ within tumors, which synNotch CARs then recognize to clear solid tumors.

    Why it matters: Speaker uses ultrasound as an external switch for CAR-T activity and intratumoral antigen induction, with mouse data on lacking ideal antigens and dose-limiting toxicity.

Oct 15Thu
  1. Cell79

    Mitochondria-targeted tetraoxanes initiate lipid peroxidation to drive ferroptosis and tumor suppression

    Tetraoxane compounds WMK-1/2 trigger a distinct "mito-ferroptosis" sub-pathway by initiating mitochondrial lipid peroxidation, bypassing GPX4- and retinol-mediated defenses. The compounds showed potent, bioavailable tumor suppression across multiple in vivo models, defining them as first-generation mitochondrial lipid peroxidation inducers.

    Why it matters: Identifies a mitochondrial ferroptosis route that evades known defenses, with in vivo tumor suppression.

  2. EMA90

    EMA recommends authorisation of Rasonque for metastatic pancreatic cancer

    EMA's human medicines committee (CHMP) has recommended EU approval of the oral RAS inhibitor Rasonque (daraxonrasib) for adults with previously treated metastatic pancreatic adenocarcinoma. The applicant is Revolution Medicines. A phase 3 study enrolled 500 patients, 92% of whom carried a RAS G12 mutation; median overall survival was 12.4 months with Rasonque versus 6.7 months with chemotherapy, and median progression-free survival was 7.2 versus 3.6 months.

    Why it matters: The brief gives median OS of 12.4 versus 6.7 months and PFS of 7.2 versus 3.6 months, letting readers gauge clinical benefit.

  3. WeChat66

    In Vivo LNP-Generated CAR-NK Cells: NKG2A Targeting Beats NKG2D in Tumor Models

    Targeted lipid nanoparticles (LNPs) generated CAR-NK cells directly inside mice, produced by the MIT team of Daniel Anderson and Robert Langer and published in Nature Biotechnology on October 13. LNPs targeting NKG2A transfected NK cells less efficiently than NKG2D-targeted LNPs in some experiments, yet blocked the inhibitory NKG2A signal and gave better outcomes in certain tumor models. Targeting ligand biology, not just delivery efficiency, shapes therapeutic effect.

    Why it matters: Shows ligand biology can matter more than transfection efficiency for in vivo immune cell delivery.

  4. WeChat69

    Gilead Licenses Vir Biotechnology PRO-XTEN Technology in $1.9 Billion Solid Tumor T-cell Engager Deal

    Vir Biotechnology has signed a collaboration and licensing agreement with Gilead Sciences worth up to $1.9 billion, announced October 14, 2026 in San Francisco. Vir will discover, design and optimize three PRO-XTEN double-masked T-cell engager candidates against selected solid tumor-associated antigens, while Gilead obtains an exclusive license to develop, manufacture and commercialize candidates arising from the work.

    Why it matters: Large-value oncology licensing deal between two named companies covering solid tumor T-cell engagers.

  5. WeChat81

    VERIFY Phase 3: Rusfertide Improves Hematocrit Control and Cuts Phlebotomy Need in Polycythemia Vera

    Rusfertide improved hematocrit control in polycythemia vera patients who were phlebotomy-dependent with poorly controlled hematocrit. In the VERIFY phase 3 study, 77% of rusfertide patients needed no phlebotomy between weeks 20 and 32 versus 33% of controls, and 63% maintained hematocrit below 45% versus 14%, with mean phlebotomies of 0.5 versus 1.8 (all P<.0001). It offers an alternative to repeated phlebotomy in these patients.

    Why it matters: Phase 3 data show rusfertide reduced phlebotomy dependence in polycythemia vera across multiple endpoints.

  6. New England Journal of Medicine54

    Ponatinib–Blinatumomab or Imatinib–Chemotherapy for Adult Ph-Positive ALL

    Italy's GIMEMA collaborative group published a randomized controlled trial in NEJM involving adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), comparing ponatinib plus blinatumomab against imatinib plus chemotherapy. The feed only provides the journal citation (Volume 395, Issue 15, 1483-1494); no full abstract was given.

    Why it matters: Traffic: 6401 views; 2 sources reported the same event.

  7. 监管与产业动态52

    FDA clears ImmunityBio’s Anktiva expansion in bladder cancer after regulatory whiplash - Fierce Pharma

    The FDA has approved an expanded indication for ImmunityBio's Anktiva in bladder cancer, ending earlier regulatory setbacks. The source material contains only the headline; the approval scope, trial data and timeline are not given in the current materials.

    Why it matters: Hot story: reported by four sources covering the same event.

  8. WeChat68

    Blood Regulatory T Cell Changes May Precede Lung Cancer Formation, Nature Study Finds

    A UCL-led study published in Nature examines whether immune changes in blood precede lung cancer formation. The work, Gamble S et al., 'A preinvasive regulatory T cell axis for lung cancer interception', investigates regulatory T cells as a potential axis for intercepting lung cancer before it becomes invasive. The findings point to blood immune-cell changes as a possible early marker of disease.

    Why it matters: Suggests blood regulatory T cell changes may enable interception of lung cancer before invasion.

  9. BioPharma Dive61

    Iambic, an AI drug discovery specialist, banks $150M in an IPO

    Iambic Therapeutics, an AI drug discovery startup, raised $150 million in an IPO, selling close to 9.4 million shares at $16 each and trading on the Nasdaq from Thursday under the ticker "IAM." The company has drawn $462 million in private funding since 2019 and will use the proceeds to advance its first drug, IAM1363, an oral tyrosine kinase inhibitor for HER2-positive solid tumors that showed anti-tumor activity and encouraging safety in a Phase 1 study, with a registrational trial possibly beginning in 2027. Behind it are IAM217, targeting KIF18A in ovarian and triple-negative breast cancers, and a CDK2/CDK4-targeting prospect, both potentially entering testing next year.

    Why it matters: The offering adds to a wave of AI drug discovery startups testing whether public investors will back the technology.

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org